Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
- Michael B. Atkins
- , Opeyemi A. Jegede
- , Naomi B. Haas
- , David F. McDermott
- , Mehmet A. Bilen
- , Mark Stein
- , Jeffrey Sosman
- , Robert Alter
- , Elizabeth R. Plimack
- , Moshe C. Ornstein
- , Michael Hurwitz
- , David J. Peace
- , David Einstein
- , Paul J. Catalano
- , Hans Hammers
- , Meredith M. Regan
- Georgetown University
- Dana-Farber Cancer Institute
- University of Pennsylvania
- Beth Israel Deaconess Medical Center
- Emory University
- Columbia University
- Northwestern University
- John Theurer Cancer Center
- Cleveland Clinic Foundation
- Yale University
- University of Illinois at Chicago
- University of Texas Southwestern Medical Center
Research output: Contribution to journal › Article › peer-review
7
Scopus
citations